Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2018-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2018.04.036PMID 29691156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reviving the guardian of the genome: Small molecule activators of p53

  2017cited by this paper
• Skeletal Diversity in Combinatorial Fashion: A New Format for the Castagnoli-Cushman Reaction.

  2017cited by this paper
• Putting p53 in Context.

  2017cited by this paper
• The Ecstasy and Agony of Assay Interference Compounds

  2017cited by this paper
• Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.

  2017cited by this paper
• The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

  2016cited by this paper
• Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

  2016cited by this paper
• Current diversity of cyclic anhydrides for the Castagnoli–Cushman-type formal cycloaddition reactions: prospects and challenges

  2016cited by this paper
• Clinical Overview of MDM2/X-Targeted Therapies

  2016cited by this paper
• Unveiling the "Three-Finger Pharmacophore" Required for p53-MDM2 Inhibition by Saturation-Transfer Difference (STD) NMR Initial Growth-Rates Approach.

  2016cited by this paper
• Diastereotopic derivatives of chiral alkoxyisoindolinones

  2016cited by this paper
• New Heterocyclic Product Space for the Castagnoli-Cushman Three-Component Reaction.

  2015cited by this paper
• Discovery of Novel Isatin-Based p53 Inducers.

  2015cited by this paper
• Pharmacological reactivation of p53 as a strategy to treat cancer

  2015cited by this paper
• Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

  2014cited by this paper
• Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.

  2014cited by this paper
• Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

  2014cited by this paper
• Hot spot-based design of small-molecule inhibitors for protein-protein interactions.

  2014cited by this paper
• Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

  2014cited by this paper
• Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

  2014cited by this paper
• Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

  2013cited by this paper
• Lysine-specific modifications of p53: a matter of life and death?

  2013cited by this paper
• The MDM2-p53 pathway revisited

  2013cited by this paper
• Rational design and binding mode duality of MDM2-p53 inhibitors.

  2013cited by this paper
• The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.

  2013cited by this paper
• ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse Reactions

  2012cited by this paper
• Structure-based design of novel inhibitors of the MDM2-p53 interaction.

  2012cited by this paper
• Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity.

  2012cited by this paper
• Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells

  2010cited by this paper
• New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

  2010cited by this paper
• Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS

  2009cited by this paper
• Ubiquitination and Degradation of Mutant p53

  2007cited by this paper
• PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching

  2006cited by this paper
• Pilot screening programme for small molecule activators of p53

  2005cited by this paper
• 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

  2005cited by this paper
• Control of apoptosis by p53

  2003cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper

• Ambiguous Role of p53 in Transcription-Dependent Tumor Cell Death

  2026cites this paper
• Ubiquitin recruiting chimera: more than just a PROTAC

  2024cites this paper
• p53: The Multifaceted Roles of Covalent Modifications in Cancer

  2024cites this paper
• PROTAC-attractive site as a new target for suppressing P-glycoprotein activity.

  2024cites this paper
• Castagnoli‐Cushman Reaction of 3‐Aryl Glutaric Acids: A Convenient, Diastereoselective Reaction for 6‐Oxo‐2,4‐diarylpiperidine‐3‐carboxylic Acid Scaffold

  2022cites this paper
• Analysis of P-Glycoprotein Transport Cycle Reveals a New Way to Identify Efflux Inhibitors

  2022cites this paper
• ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.

  2022cites this paper
• Microwave accelerated Castagnoli-Cushman reaction: Synthesis of novel 6,7,8,9-tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazines

  2021cites this paper
• Establishment of drug-resistant cell lines under the treatment with chemicals acting through different mechanisms.

  2021cites this paper
• Selected Conference Abstracts from “The Regulation of Proteostasis in Cancer”

  2020cites this paper
• Activating Effect of 3‐Benzylidene Oxindoles on AMPK: From Computer Simulation to High‐Content Screening

  2020cites this paper
• Treatment of chemoresistant cell lines with indolinone-based small molecules

  2020cites this paper
• Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors.

  2020cites this paper
• From random to rational: A discovery approach to selective subnanomolar inhibitors of human carbonic anhydrase IV based on the Castagnoli-Cushman multicomponent reaction.

  2019cites this paper
• Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction

  2019cites this paper